James Barder, chief executive of Futura Medical plc. (LON:FUM) tells Proactive's Andrew Scott they've had a very productive six months as their breakthrough erectile dysfunction gel moves closer to its phase III study.
A mid-stage trial last September showed that MED2002 gets to work quicker than its competitors and has a favourable safety profile.
Futura also has its CSD500 erectogenic condom which was launched in Saudi Arabia at the beginning of the year.
They were dealt a blow by one its licensing partners, Church & Dwight Co Inc (NYSE:CHD), in August after it terminated its licensing agreement for CSD500 following a strange of strategy.